Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1.
- Author:
Kai LIANG
1
;
De-Xiang LU
;
Ning CHU
;
Jie CHENG
Author Information
- Publication Type:Journal Article
- MeSH: Cell Line, Tumor; Cell Proliferation; drug effects; Humans; Male; Prostate; metabolism; Prostatic Neoplasms; metabolism; pathology; Ribosomal Protein S6 Kinases, 70-kDa; metabolism; Sirolimus; pharmacology
- From: National Journal of Andrology 2012;18(4):327-330
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effects of rapamycin on the proliferation of prostate cancer cell line 22RV1 and the activity of S6K1.
METHODSProstate cancer 22RV1 cells cultured in vitro were treated with rapamycin at the concentrations of 0, 50, 100, 200 and 400 nmol/L. The inhibition rate of the cells'proliferation was detected by MTT, and the activity of S6K1 was determined by liquid scintillation counting.
RESULTSRapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P<0.01).
CONCLUSIONRapamycin can effectively suppress the proliferation of prostate cancer 22RV1 cells by regulating the expression of S6K1, the downstream protein of mammalian target of rapamycin (mTOR).
